Beyond monoclonal antibodies: constraints and the case for alternative PD-1/PD-L1-targeting formats. [PDF]
Front ImmunolPorozova NO +6 more
europepmc +1 more source
SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy. [PDF]
Mol CancerLi J +8 more
europepmc +1 more source
Probing the Immunoreceptor Tyrosine-Based Inhibition Motif Interaction Protein Partners with Proteomics. [PDF]
MoleculesGao Y, Xing S, Hu L.
europepmc +1 more source
Nanomedicine targeting the PD-1/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance. [PDF]
J NanobiotechnologyXiang G +6 more
europepmc +1 more source
The Search for Predictive Biomarkers in Response to Immune Checkpoint Inhibitors and Associated Adverse Events. [PDF]
J Pers MedAgostini M, Traldi P, Hamdan M.
europepmc +1 more source
Dissecting the Ability of Siglecs To Antagonize Fcγ Receptors. [PDF]
ACS Cent SciMcCord KA +6 more
europepmc +1 more source
Investigating the effect of ceramic fiber on the mechanical properties of glassphalt. [PDF]
Sci RepDehnad MH, Yazdi A, Hamedi GH.
europepmc +1 more source
Genetic Interruption of PD-1/PD-L1 as an Alternative Means for Immune Checkpoint Blockade in Cancer: A Review. [PDF]
PharmaceuticsLi D, Lu J, Li Q, Deng H, Tan S.
europepmc +1 more source
Molecular mechanisms and potential targeting strategies of ubiquitin‑proteasome system‑mediated PD‑1/PD‑L1 ubiquitination in tumor immune suppression (Review). [PDF]
Oncol RepGu LH +6 more
europepmc +1 more source
Anti-Tumor Potential of Post-Translational Modifications of PD-1. [PDF]
Curr Issues Mol BiolXi X, Zhao W.
europepmc +1 more source